Corcept Therapeutics (CORT) Competitors $74.12 +2.80 (+3.92%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. ANVS, RPRX, JAZZ, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Annovis Bio (ANVS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector. Corcept Therapeutics vs. Its Competitors Annovis Bio Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Which has more volatility and risk, CORT or ANVS? Corcept Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Do insiders & institutionals have more ownership in CORT or ANVS? 93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to CORT or ANVS? In the previous week, Corcept Therapeutics had 19 more articles in the media than Annovis Bio. MarketBeat recorded 21 mentions for Corcept Therapeutics and 2 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 1.06 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend CORT or ANVS? Corcept Therapeutics presently has a consensus price target of $135.25, suggesting a potential upside of 82.48%. Annovis Bio has a consensus price target of $17.33, suggesting a potential upside of 619.23%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is CORT or ANVS more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 20.10% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics18.51% 20.10% 16.20% Annovis Bio N/A -206.01%-158.26% Which has stronger earnings and valuation, CORT or ANVS? Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$675.04M11.57$141.21M$1.1365.59Annovis BioN/AN/A-$24.59M-$2.04-1.18 SummaryCorcept Therapeutics beats Annovis Bio on 12 of the 15 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.80B$2.55B$5.76B$10.26BDividend YieldN/A56.56%5.88%4.63%P/E Ratio65.5423.5576.5826.64Price / Sales11.57668.05525.00124.82Price / Cash55.98169.4937.1760.46Price / Book11.425.3714.156.31Net Income$141.21M$32.95M$3.29B$271.01M7 Day Performance3.49%1.60%1.28%2.40%1 Month Performance3.30%4.88%5.01%6.77%1 Year Performance86.64%-3.70%86.96%27.26% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.8006 of 5 stars$74.12+3.9%$135.25+82.5%+85.4%$7.80B$675.04M65.54300Positive NewsANVSAnnovis Bio2.1128 of 5 stars$2.42-2.6%$17.33+617.7%-70.3%$47.07MN/A-1.183News CoverageRPRXRoyalty Pharma4.8197 of 5 stars$35.15-3.3%$48.00+36.6%+25.3%$20.50B$2.26B20.3280JAZZJazz Pharmaceuticals4.5333 of 5 stars$125.22-0.7%$178.67+42.7%+15.5%$7.60B$4.09B-18.612,800Positive NewsPRGOPerrigo4.8961 of 5 stars$21.76-2.3%$33.00+51.7%-24.3%$2.99B$4.37B-37.518,379Positive NewsSUPNSupernus Pharmaceuticals2.7578 of 5 stars$43.99-3.2%$43.00-2.3%+39.7%$2.47B$665.13M38.25580Positive NewsInsider TradePCRXPacira BioSciences3.396 of 5 stars$26.86-1.0%$30.83+14.8%+96.5%$1.21B$700.97M-9.66720Positive NewsNKTRNektar Therapeutics4.1674 of 5 stars$49.01+0.7%$88.33+80.2%+161.9%$932.17M$98.43M-5.57220Positive NewsOMEROmeros4.0166 of 5 stars$4.09-1.4%$18.00+340.1%+3.3%$278.37MN/A-1.94210Positive NewsASMBAssembly Biosciences3.3109 of 5 stars$21.19-3.0%$41.33+95.1%+12.0%$162.57M$33.25M-3.80100Short Interest ↑CPIXCumberland Pharmaceuticals0.6154 of 5 stars$3.38-1.7%N/A+168.8%$50.57M$42.07M-15.3680Positive News Related Companies and Tools Related Companies Annovis Bio Competitors Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
